PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Empagliflozin/linagliptin single-pill combination therapy for patients with type 2 diabetes mellitus.

Abstract Type 2 diabetes mellitus (T2DM) is typically progressive, with sequential addition of therapies often needed to address increasing hyperglycemia over the disease course. Using treatments in combination may be preferred to sequential addition, as a means of providing a more rapid clinical response and potentially avoiding clinical inertia. In such cases, a single-pill combination can help to reduce pill burden. Although various single-pill combinations of oral glucose-lowering agents are available, empagliflozin/linagliptin was the first approved combination of a sodium glucose co-transporter 2 (SGLT2) inhibitor with a dipeptidyl peptidase 4 (DPP-4) inhibitor in the United States. Areas covered: Two publications of the clinical trial investigating the efficacy and safety of single-pill combinations of empagliflozin/linagliptin in treatment-naive or metformin-treated patients with T2DM (NCT01422876) are reviewed, and their potential impact on clinical practice is discussed. Expert opinion: The study discussed provides evidence for the efficacy and safety of empagliflozin/linagliptin single pills. Addition of an empagliflozin/linagliptin single pill may be considered in patients with inadequate glycemic control on metformin, or as an alternative to first-line treatment with empagliflozin or linagliptin when metformin is not suitable, particularly in patients with very poor glycemic control, or those who need to achieve target more quickly.
PMID
Related Publications

Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus.

Empagliflozin/Linagliptin: Combination therapy in patients with type 2 diabetes.

Empagliflozin/Linagliptin: A Review in Type 2 Diabetes.

Empagliflozin/linagliptin single-tablet combination: first-in-class treatment option.

Single-pill combination therapy for type 2 diabetes mellitus: linagliptin plus empagliflozin.

Authors

Mayor MeshTerms
Keywords

DPP-4 inhibitors

SGLT2 inhibitors

empagliflozin

linagliptin

metformin

phase III clinical trial

single-pill combination therapy

type 2 diabetes mellitus

Journal Title expert opinion on pharmacotherapy
Publication Year Start




PMID- 28375658
OWN - NLM
STAT- MEDLINE
DA  - 20170404
DCOM- 20170417
LR  - 20170417
IS  - 1744-7666 (Electronic)
IS  - 1465-6566 (Linking)
VI  - 18
IP  - 6
DP  - 2017 Apr
TI  - Empagliflozin/linagliptin single-pill combination therapy for patients with type 
      2 diabetes mellitus.
PG  - 545-549
LID - 10.1080/14656566.2017.1299712 [doi]
AB  - INTRODUCTION: Type 2 diabetes mellitus (T2DM) is typically progressive, with
      sequential addition of therapies often needed to address increasing hyperglycemia
      over the disease course. Using treatments in combination may be preferred to
      sequential addition, as a means of providing a more rapid clinical response and
      potentially avoiding clinical inertia. In such cases, a single-pill combination
      can help to reduce pill burden. Although various single-pill combinations of oral
      glucose-lowering agents are available, empagliflozin/linagliptin was the first
      approved combination of a sodium glucose co-transporter 2 (SGLT2) inhibitor with 
      a dipeptidyl peptidase 4 (DPP-4) inhibitor in the United States. Areas covered:
      Two publications of the clinical trial investigating the efficacy and safety of
      single-pill combinations of empagliflozin/linagliptin in treatment-naive or
      metformin-treated patients with T2DM (NCT01422876) are reviewed, and their
      potential impact on clinical practice is discussed. Expert opinion: The study
      discussed provides evidence for the efficacy and safety of
      empagliflozin/linagliptin single pills. Addition of an empagliflozin/linagliptin 
      single pill may be considered in patients with inadequate glycemic control on
      metformin, or as an alternative to first-line treatment with empagliflozin or
      linagliptin when metformin is not suitable, particularly in patients with very
      poor glycemic control, or those who need to achieve target more quickly.
FAU - Jain, Rajeev Kumar
AU  - Jain RK
AD  - a Aurora Health Center , Aurora Advanced Healthcare, Inc ., Milwaukee , WI , USA.
LA  - eng
PT  - Journal Article
DEP - 20170404
PL  - England
TA  - Expert Opin Pharmacother
JT  - Expert opinion on pharmacotherapy
JID - 100897346
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Blood Glucose)
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Drug Combinations)
RN  - 0 (Glucosides)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sodium-Glucose Transporter 2)
RN  - 3X29ZEJ4R2 (Linagliptin)
RN  - 9100L32L2N (Metformin)
RN  - HDC1R2M35U (empagliflozin)
SB  - IM
MH  - Adult
MH  - Benzhydryl Compounds/*administration & dosage
MH  - Blood Glucose/drug effects
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Dipeptidyl-Peptidase IV Inhibitors/therapeutic use
MH  - Drug Combinations
MH  - Glucosides/*administration & dosage
MH  - Humans
MH  - Hyperglycemia/drug therapy
MH  - Hypoglycemic Agents/*administration & dosage/therapeutic use
MH  - Linagliptin/*administration & dosage
MH  - Metformin/therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Sodium-Glucose Transporter 2/antagonists & inhibitors
OTO - NOTNLM
OT  - DPP-4 inhibitors
OT  - SGLT2 inhibitors
OT  - empagliflozin
OT  - linagliptin
OT  - metformin
OT  - phase III clinical trial
OT  - single-pill combination therapy
OT  - type 2 diabetes mellitus
EDAT- 2017/04/05 06:00
MHDA- 2017/04/18 06:00
CRDT- 2017/04/05 06:00
AID - 10.1080/14656566.2017.1299712 [doi]
PST - ppublish
SO  - Expert Opin Pharmacother. 2017 Apr;18(6):545-549. doi:
      10.1080/14656566.2017.1299712. Epub 2017 Apr 4.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>